(An active ingredient is what makes a drug work.) Keytruda is a biologic medication. A biologic is made from parts of living organisms. It’s available only as a brand-name drug. Keytruda isn’t ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Defensive industries, like healthcare, are more attractive to income investors. That's because companies in this sector are ...

Merck & Co. on Wednesday said a late-stage study of a combination including its blockbuster cancer drug Keytruda missed its goal in certain patients with colorectal cancer. The Rahway, N.J ...

Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab, sold under brand name Keytruda, in a Phase 3 trial involving lung-cancer patients. Merck shares, which were up ...

Natalizumab eventually ended up as Tysabri, Biogen’s drug for multiple sclerosis ... in a host of cancer indications under the brand name Keytruda.

Merck's most important product is Keytruda, a cancer drug that has won approval to treat ... Not everything will make it to market, but I expect many brand-new approvals and label expansions ...

Merck's new products have mitigated the generic competition, offsetting the recent major patent losses. In particular, Keytruda for cancer represents a key blockbuster with multi-billion-dollar ...

And last year, it became the best-selling drug worldwide, taking over from the immunology superstar Humira. However, Keytruda won't ... Some of the company's recent brand-new approvals will ...

But many other modes of immunotherapy for cancer were approved first — checkpoint blockade drugs like Keytruda and engineered immune cell therapies like Yescarta. Shadowed by the successes of ...

Keytruda has previously been approved by the Food and Drug Administration as monotherapy and in combination with other therapies for some patients with metastatic or unresectable, recurrent head and ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...